US EditionPublished • loading... • Updated
Kahimmune Therapeutics Enters Licensing Agreement with Gustave Roussy and SATT Paris-Saclay
Summary by pharmatimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Kahimmune Therapeutics signs exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay - Oncology Today
Kahimmune Therapeutics, a biotechnology company developing next-generation immuno-oncology therapies, today announces the signing of an exclusive licensing agreement with Gustave Roussy, the European leader in oncology, and SATT Paris-Saclay, experts in technology transfer. Created at the end of 2025, Kahimmune draws on the latest discoveries in immunology relating to the dark genome. Non-coding RNAs represent 98% of our DNA, yet we currently kn…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
